Purified CARCIK-CD19 or unmodified CIK with the addition of blinatumomab were then evaluated for their ability to mount an in vitro anti-leukemia cytotoxic response against two CD19+ cell lines, the B-ALL REH and the Burkitt lymphoma Daudi. Here, CD19 is linked to Burkitt lymphoma.